PRS11
ANALYSIS OF OXALIPLATIN-INDUCED ALLERGIC REACTIONS AND THE EFFECTIVENESS OF RECEIVING PREVENTIVE ANTIHISTAMINE DRUGS
Wu J*, Kou H$, Wang H$$1
1Chi-Mei medical center, Tainan, Taiwan, $Kaohsiung Medical University, Kaohsiung, Taiwan

OBJECTIVES: Oxaliplatin is currently one of the most cytotoxic drugs for several cancers. In recent years, increasing incidence of oxaliplatin-induced allergic reactions was reported. Severe allergic reactions even interrupted ongoing oxaliplatin treatments. Many doctors gave the patients preventive antihistamine Drugs before oxaliplatin infusions. However, on the one hand, antihistamine drugs often cause dizziness or conscious disturbance. On the other side, antihistamine drugs cannot prevent some patients effectively from oxaliplatin-induced allergic reactions by clinical observation. METHODS: This is a retrospective case-control study. Patients receiving oxaliplatin from 2008 to 2013 in a medical center in southern Taiwan were included and divided into two groups. The study group consisted of patients without taking antihistamine drugs before oxaliplatin infusions, while the control group included patients taking antihistamine drugs before oxaliplatin infusions. We analyzed the incidence and the grade of oxaliplatin-induced allergic reactions and the cost of antihistamine drugs.

RESULTS: There were 335 patients included for analysis. There were 164 patients in the study group, and 371 patients in the control group. Allergic reactions happened to 27 patients (16.46%) in the study group, while 58 patients (55.22%) in the control group (95% CI: 0.571-1.548, p > 0.05). 15 patients (9.15%) had mild allergic reactions and 12 patients (7.32%) moderate and severe in the study group; 36 patients (9.73%) had mild allergic reactions and 22 patients (5.93%) moderate and severe in the control group (95% CI: 0.303-1.928; p > 0.05). The cost of antihistamine drugs and consumables was about NTD 66,000 per year.

CONCLUSIONS: The study reveals that antihistamine drugs to prevent oxaliplatin-induced allergic reactions had no statistically significant difference from that in the control group. Preventive antihistamine drugs not only cause dizziness or conscious disturbance but also increase the cost of treatments.

PRS12
RESPIRATORY SyncytIAL VIRUS PROPHYLAXIS IN DOWN SYNDROME: A PROSPECTIVE COHORT STUDY
Ye H1, Lancot KL2, Bonni LT3, Bloemers B4, van Forth M5, Li A5, Kiss A5, Mitchell IP, Paes BA

1Sunbury Health Sciences Centre, Toronto, ON, Canada, 2UCMC Utrecht, Utrecht, The Netherlands, 3YU University Centre, Amsterdam, The Netherlands, 4’University of Calgary, Calgary, AB, Canada, 5McMaster University, Hamilton, ON, Canada

OBJECTIVES: Children with Down syndrome (DS) are at significant risk for respiratory tract (RT) and respiratory syncytial virus (RSV) infections and related hospitalization. We compared hospitalization rates for RTI in DS children aged 2 years who prospectively received palivizumab during the RSV season versus a previously published, similar untreated DS birth cohort. METHODS: 532 prophyllaized and 134 untreated DS children were identified from an RSV immunoprophylaxis registry (CARESS) between the years 2005-2012. The untreated group comprised 233 DS children derived from a Dutch, nation-wide birth cohort from 2003-2005. Events during the RSV season were counted. Demographics and risk factors were compared using t-test or chi-square if appropriate. Poisson regression analysis was performed to compare incidence rate ratios (95% CI) for both RTI and confirmed RSV hospitalization between the groups while controlling for observation length and other factors for severe RSV infections. RESULTS: In total, 31 (23 untreated, 8 treated) RSV-related hospitalizations were documented. The adjusted risk of RSV-related hospitalizations was higher in untreated subjects compared to palivizumab-treated subjects (incidence rate ratio 3.63 [95% CI: 1.52-8.67], p = 0.05). The adjusted risk for hospitalization for all respiratory tract infection (147 events; 73 untreated, 74 treated) was similar (incidence rate ratio untreated versus palivizumab 1.01 [95% CI: 0.65-1.55]). CONCLUSIONS: These results suggest that palivizumab is associated with a 3.6-fold reduction in the incidence rate ratio for RSV-related hospitalization in children with DS aged < 2 years. A randomized trial is needed to determine the efficacy of RSV immunoprophylaxis in this specific high-risk patient population.

PRS13
PREVALENCE AND INCIDENCE OF INTERSTITIAL PULMONARY DISEASES WITH FIBROSIS
Hopkins RB1, Burke N2, Koll M3, Fell C1, Greene R4
1PATH Research Institute, McMaster University, Hamilton, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3University of Calgary, Calgary, AB, Canada

OBJECTIVES: Other interstitial pulmonary diseases with fibrosis (OIPDF) classified by ICD-10 CA code J84.1 are rare with unknown prevalence at the national level in Canada. ICD-10 CA includes diffuse pulmonary fibrosis, fibrosing alveolitis (cryptogenic), Hamman-Rich syndrome, idiopathic pulmonary fibrosis, and usual interstitial pneumonia. To estimate the prevalence and incidence of OIPDF in Canada in 2010, we used mandatory standardized national administrative data from fiscal years 2006 to 2011 to identify OIPDF cases aged 50+ with an ICD-10 CA diagnosis code of J84.1 from acute care admissions, emergency room visits, day surgery and in-hospital respiratory clinics. Cases were required to have computed tomography, bronchoscopy, and/or pulmonary function tests to support the OIPDF diagnosis. We used a subsequent diagnosis of other interstitial lung disease after the OIPDF diagnosis. We compared the rates of prevalence to incidence and investigated the rates of death with Cox proportional hazard analysis. National estimates for prevalence and incidence risk of death were compared for OIPDF versus COPD. RESULTS: In Canada for the year 2010 for ages 50+, the prevalence of OIPDF was 6.307 (54.1/100,000) and incidence was 2,804 (24.6/100,000) cases. The low ratio of prevalence to incidence (2.2) existed because of a higher mortality risk. The adjusted risk of OIPDF compared to all other interstitial diseases was 1.1 (95% CI: 0.67-2.0). The adjusted risk of death for OIPDF was 28.9% of all deaths from COPD, while the prevalence of OIPDF was 2.9% of all COPD cases. CONCLUSIONS: OIPDF is an important disease with a high death rate and non-trivial prevalence and incidence rates. However, there were wide variations in the rates of incidence and prevalence across the provinces, and the national estimates were higher than reported from other countries. Further research at the provincial level is forthcoming to validate the national estimates.

PRS14
VARIATION TRENDS IN ASTHMA PREVALENCE IN THE UNITED STATES 1980-2010: NATIONAL POPULATION
Wang L1, Xie L2, Zhang J3, Shrestha S1, Wang Y4, Baser O5
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3STATinMED Research and The University of Michigan, Ann Arbor, MI, USA

OBJECTIVES: The goal of this study was to examine state, age and gender as well as racial and geographic variations in asthma prevalence among U.S. Medicaid patients. METHODS: Patients diagnosed with asthma (International Classification of Disease, 9th Revision, Clinical Modification [ICD-9-CM] diagnosis code 493.xx) were included in a retrospective study (January 1, 2008 to December 31, 2009) from a Medicaid fee-for-service (FFS) population. All patients were required to have a 2-year continuous Medicaid FFS enrollment in 2008 and 2009. Patients with managed care enrollment in any month during the study period were excluded. Disease prevalence was stratified by region, state, age, gender and race for all the patients. Descriptive statistics were calculated as the number and percentage of patients in each category to make prevalence and incidence rates for the sample. RESULTS: A total of 399,572 patients were diagnosed with asthma in 2008 and 2009. For asthma patients, prevalence was the highest for those under age 40 (10.59%), followed by age groups 40 to 59 (10.45%), and over 60 (4.65%). Asthma prevalence by Hispanic race was 4.7% (793.7), White (7.8%), Hispanic (7.18%) and Asian (6.06%). Higher asthma prevalence rates were observed for female (8.69%) compared to male patients (7.78%). Geographic variation was analyzed with the highest asthma prevalence observed in Missouri (14.04%), followed by New Hampshire (13.19%), Connecticut (13.12%), Ohio (12.96%) and Minnesota (12.52%). Prevalence rates were found to be highest in the Midwest (10.43%) compared to the Northeast (8.65%), West (6.96%) and Southern (6.3%) U.S. regions. CONCLUSIONS: The current study shows that patients under the age of 60 have a higher probability of being diagnosed with asthma. Moreover, Native American and Black patients were more likely to be diagnosed with asthma compared to other races. Geographically, patients residing in the Midwest U.S. region have a higher risk for an asthma diagnosis.

PRS15
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS: A RISK FACTOR FOR ASTHMA AND ALLERGIES? PRELIMINARY FINDINGS FROM A SYSTEMATIC REVIEW
Cahubes B1, Uphoff E2, Pinart M1, Wright J1, Anto JM1
1Department of the Development Clinical Allema, Chile, Santiago, Chile, 2Bradford Institute for Health Research, Bradford, UK, 3Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain

OBJECTIVES: There is a huge burden of disease for childhood asthma and allergies. Methicillin resistant Staphylococcus aureus (MRSA) acts as a potential risk factor for asthma and allergies and is controversial; therefore, we aimed at assessing the international evidence for the association between migration status and asthma and allergies. METHODS: We performed a systematic review of 40 studies. SRATA presented the results in accordance with the guidelines set by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The search was conducted in the PubMed database in November 2012 and we chose broad string and MeSH terms in our search to include any definition of asthma and allergies, and migration status. From the total of 2737 unique hits identified through the search, 127 studies were selected for a full-text review. After reviewing full-text papers, 5 studies were selected for data extraction and synthesis. RESULTS: The prevalence of asthma and allergies in newly arrived immigrants appeared to be similar to prevalences

A171